Journal Article
. 2017 Jan; 35(10):1041-1048.
doi: 10.1200/JCO.2016.69.2871.

Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial

Ian Smith 1 Denise Yardley 1 Howard Burris 1 Richard De Boer 1 Dino Amadori 1 Kristi McIntyre 1 Bent Ejlertsen 1 Michael Gnant 1 Walter Jonat 1 Kathleen I Pritchard 1 Mitch Dowsett 1 Lowell Hart 1 Susan Poggio 1 Lisa Comarella 1 Herve Salomon 1 Barbara Wamil 1 Joyce O'Shaughnessy 1 
Affiliations
  • PMID: 28113032
  •     26 citations

Abstract

Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -positive and node-positive early breast cancer (eBC). Methods Postmenopausal women with HR-positive and node-positive eBC were randomly assigned to receive adjuvant therapy with either letrozole (2.5 mg) or anastrozole (1 mg) once per day for 5 years or until recurrence of disease. Patients were stratified on the basis of the number of lymph nodes and human epidermal growth factor receptor 2 status. The primary end point was 5-year disease-free survival (DFS), and the key secondary end points were overall survival and safety. Results A total of 4,136 patients were randomly assigned to receive either letrozole (n = 2,061) or anastrozole (n = 2,075). The final analysis was done at 709 DFS events (letrozole, 341 [16.5%]; anastrozole, 368 [17.7%]). The 5-year estimated DFS rate was 84.9% for letrozole versus 82.9% for anastrozole arm (hazard ratio, 0.93; 95% CI, 0.80 to 1.07; P = .3150). Exploratory analysis showed similar DFS with letrozole and anastrozole in all evaluated subgroups. The 5-year estimated overall survival rate was 89.9% for letrozole versus 89.2% for anastrozole arm (hazard ratio, 0.98; 95% CI, 0.82 to 1.17; P = .7916). Most common grade 3 to 4 adverse events (> 5% of patients) reported for letrozole versus anastrozole were arthralgia (3.9% v 3.3%, and 48.2% v 47.9% for all adverse events), hypertension (1.2% v 1.0%), hot flushes (0.8% v 0.4%), myalgia (0.8% v 0.7%), dyspnea (0.8% v 0.5%), and depression (0.8% v 0.6%). Conclusion Letrozole did not demonstrate significantly superior efficacy or safety compared with anastrozole in postmenopausal patients with HR-positive, node-positive eBC.

Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery.
Angel L Guerrero-Zotano, Carlos L Arteaga.
Cancer Discov, 2017 May 13; 7(6). PMID: 28495849    Free PMC article.
Review.
Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.
Daniel L Hertz, Kelly A Speth, +8 authors, James M Rae.
Breast Cancer Res Treat, 2017 Jun 24; 165(3). PMID: 28643023    Free PMC article.
Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis.
Zhu Yu, Xiaojing Guo, +5 authors, Haitian Zhang.
Breast Cancer, 2017 Jul 30; 25(1). PMID: 28755088    Free PMC article.
Review.
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
G Curigliano, H J Burstein, +52 authors, B Xu.
Ann Oncol, 2017 Aug 26; 28(8). PMID: 28838210    Free PMC article.
Highly Cited.
Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study.
Tadahiko Shien, Hiroyoshi Doihara, +12 authors, Tadashi Ikeda.
Cancer Chemother Pharmacol, 2017 Dec 03; 81(2). PMID: 29196963    Free PMC article.
Endocrine Therapy for Early Breast Cancer: Updated Review.
Alexander Tremont, Jonathan Lu, John T Cole.
Ochsner J, 2017 Dec 13; 17(4). PMID: 29230126    Free PMC article.
Review.
Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment.
Yukio Nakamura, Mikio Kamimura, +3 authors, Hiroyuki Kato.
Ther Clin Risk Manag, 2018 Mar 22; 14. PMID: 29559791    Free PMC article.
Obesity and outcome of post-menopausal women receiving adjuvant letrozole for breast cancer.
Jamal Zekri, Kamel Farag, Ahmed Allithy.
Ecancermedicalscience, 2018 Apr 18; 12. PMID: 29662534    Free PMC article.
Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines.
A Matutino, A A Joy, +2 authors, S Verma.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910656    Free PMC article.
Review.
Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK.
Claire Telford, Evelina Bertranou, +3 authors, Christopher Livings.
Pharmacoecon Open, 2019 Apr 27; 3(4). PMID: 31025302    Free PMC article.
Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.
Jacqueline M Dempsey, Kelley M Kidwell, +9 authors, Daniel L Hertz.
Pharmacogenomics, 2019 Jun 14; 20(8). PMID: 31190621    Free PMC article.
Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis.
Yang He, Jianhua Zhang, +5 authors, Dongsheng Hong.
BMC Pharmacol Toxicol, 2019 Oct 31; 20(1). PMID: 31665091    Free PMC article.
Systematic Review.
Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.
Irene E G van Hellemond, Ingeborg J H Vriens, +15 authors, Dutch Breast Cancer Research Group (BOOG).
Int J Cancer, 2018 Dec 28; 145(1). PMID: 30588619    Free PMC article.
Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis.
Alfredo Addeo, Glen J Weiss, Bishal Gyawali.
JAMA Netw Open, 2019 May 11; 2(5). PMID: 31074821    Free PMC article.
Review.
Aromatase Inhibitors and Risk of Arthritis and Carpal Tunnel Syndrome among Taiwanese Women with Breast Cancer: A Nationwide Claims Data Analysis.
Hsu-Chih Chien, Yea-Huei Kao Yang, +3 authors, Wei-Hsuan Lo-Ciganic.
J Clin Med, 2020 Feb 26; 9(2). PMID: 32092973    Free PMC article.
Aromatase Inhibitors as Adjuvant Treatment for ER/PgR Positive Stage I Endometrial Carcinoma: A Retrospective Cohort Study.
Laura Paleari, Mariangela Rutigliani, +3 authors, Andrea Decensi.
Int J Mol Sci, 2020 Mar 27; 21(6). PMID: 32210157    Free PMC article.
Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α.
James N Ingle, Junmei Cairns, +21 authors, Liewei Wang.
Clin Cancer Res, 2020 Feb 27; 26(12). PMID: 32098767    Free PMC article.
Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review.
Adam S Komorowski, Helen J MacKay, Rossanna C Pezo.
Cancer Med, 2020 May 27; 9(14). PMID: 32452660    Free PMC article.
Systematic Review.
The underreporting of phase III chemo-therapeutic clinical trial data of older patients with cancer: A systematic review.
Karlynn BrintzenhofeSzoc, Jessica L Krok-Schoen, +10 authors, Armin Shahrokni.
J Geriatr Oncol, 2020 Jan 15; 11(3). PMID: 31932259    Free PMC article.
Systematic Review.
Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.
Junmei Cairns, James N Ingle, +14 authors, Liewei Wang.
JCI Insight, 2020 Jul 24; 5(16). PMID: 32701512    Free PMC article.
Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers.
Michael Ulm, Arvind V Ramesh, +3 authors, Ramesh Narayanan.
Endocr Connect, 2019 Jan 15; 8(2). PMID: 30640710    Free PMC article.
Review.
Significance of Ovarian Function Suppression in Endocrine Therapy for Breast Cancer in Pre-Menopausal Women.
A Scharl, A Salterberg.
Geburtshilfe Frauenheilkd, 2016 May 31; 76(5). PMID: 27239060    Free PMC article.
Review.
Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2- metastatic breast cancer.
Kristoffer B Kristensen, Ida Marie Nedergaard Thomsen, +2 authors, Anders Bonde Jensen.
Breast Cancer Res Treat, 2021 Apr 11; 188(3). PMID: 33837869
Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy.
Anna Diana, Francesca Carlino, +6 authors, Michele Orditura.
Curr Treat Options Oncol, 2021 Apr 18; 22(5). PMID: 33864145    Free PMC article.
Review.
Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis.
Elizabeth M Salvo, Abril Oliva Ramirez, +4 authors, Imtiaz A Samjoo.
Breast, 2021 Mar 08; 57. PMID: 33677313    Free PMC article.
Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management.
Tara Hyder, Christopher C Marino, +2 authors, Adam M Brufsky.
Front Endocrinol (Lausanne), 2021 Aug 14; 12. PMID: 34385978    Free PMC article.
Review.